What is the appropriate mycophenolate mofetil dose for a 55‑kg adult?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 20, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Mycophenolate Mofetil Dosing for 55 kg Adult

For a 55 kg adult, the appropriate mycophenolate mofetil dose depends on the indication: for renal transplant, use 1 g twice daily (2 g/day total); for cardiac or hepatic transplant, use 1.5 g twice daily (3 g/day total); for lupus nephritis maintenance therapy, use 750-1000 mg twice daily. 1

Transplant Indications

The FDA-approved dosing is standardized by organ type rather than body weight 1:

  • Renal transplant: 1 g orally twice daily (2 g/day total dose)
  • Cardiac transplant: 1.5 g orally twice daily (3 g/day total dose)
  • Hepatic transplant: 1.5 g orally twice daily (3 g/day total dose)

For a 55 kg patient receiving renal transplant, the standard 1 g twice daily translates to approximately 18 mg/kg/day, which falls within the optimal range suggested by pharmacokinetic studies 2, 3.

Important Caveats for Transplant Patients

Severe chronic renal impairment (GFR <25 mL/min/1.73 m²) outside the immediate post-transplant period requires dose reduction—avoid doses greater than 1 g twice daily and monitor carefully 1.

Delayed graft function does not require dose adjustment, though MPAG (the inactive metabolite) accumulates 2-3 fold 1. However, MPA exposure remains comparable to patients without delayed function.

Neutropenia (ANC <1.3 × 10³/µL) mandates dose interruption or reduction 1.

Lupus Nephritis

For lupus nephritis maintenance therapy after completing initial treatment, the recommended dose of mycophenolate mofetil is 750-1000 mg twice daily 4. This translates to approximately 27-36 mg/kg/day for a 55 kg patient, which is higher than transplant dosing.

The corresponding mycophenolic acid (enteric-coated formulation) dose would be 540-720 mg twice daily 4.

Weight-Based Dosing Considerations

While FDA labeling uses fixed dosing, pharmacokinetic data reveals important nuances:

Lower body weight patients achieve higher drug exposure per mg of MMF 2, 3. Research shows that patients with lower body weight tend to have higher MPA AUC:MMF dose ratios. For a 55 kg patient, the standard 1 g twice daily dose (approximately 18 mg/kg/day) should achieve therapeutic MPA exposure of 30-60 μg·h/mL 2.

MMF exhibits nonlinear pharmacokinetics—bioavailability decreases with increasing doses 5. This means doubling the dose does not double the drug exposure, which is particularly relevant when considering dose adjustments.

Administration Recommendations

  • Administer on an empty stomach when possible (food decreases peak concentration by 40%, though total exposure is unchanged) 1
  • In stable renal transplant patients, may give with food if necessary
  • Dosing frequency matters: every 8-hour dosing maintains higher plasma levels than every 12-hour dosing, even at the same total daily dose 6

Monitoring Strategy

Given the wide pharmacokinetic variability and nonlinear dose-response relationship, therapeutic drug monitoring is valuable. Target MPA AUC of 30-60 μg·h/mL for transplant patients. For a 55 kg patient on standard dosing, this target should be achievable, but individual variation necessitates monitoring if clinical response is suboptimal 2, 5.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.